Vanda Pharmaceuticals (VNDA)
6.06
-0.06 (0.98%)
Upcoming Events
Latest Headlines
Form 4 Vanda Pharmaceuticals For: Jun 04 Filed by: McGuire Daniel Patrick
June 8, 2026 4:40 PM - SEC Filing
Form 4 Vanda Pharmaceuticals For: Jun 04 Filed by: Chrousos Phaedra
June 8, 2026 4:23 PM - SEC Filing
Form 4 Vanda Pharmaceuticals For: Jun 04 Filed by: Duncan Charles Cliff
June 8, 2026 4:22 PM - SEC Filing
Form 4 Vanda Pharmaceuticals For: Jun 04 Filed by: DUGAN RICHARD W
June 8, 2026 4:21 PM - SEC Filing
Form 4 Vanda Pharmaceuticals For: Jun 04 Filed by: Ward Anne Sempowski
June 8, 2026 4:19 PM - SEC Filing
Form 4 Vanda Pharmaceuticals For: Jun 04 Filed by: Honore Tage
June 8, 2026 4:18 PM - SEC Filing
Form 4 Vanda Pharmaceuticals For: Jun 04 Filed by: Mitchell Stephen Ray
June 8, 2026 4:15 PM - SEC Filing
Form 3 Vanda Pharmaceuticals For: Jun 04 Filed by: McGuire Daniel Patrick
June 8, 2026 4:12 PM - SEC Filing
Form S-8 Vanda Pharmaceuticals
June 5, 2026 4:45 PM - SEC Filing
Form 8-K Vanda Pharmaceuticals For: Jun 04
June 5, 2026 4:38 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)
June 4, 2026 6:42 AM - StreetInsider
Vanda receives Japan orphan drug designation for GPP treatment
May 27, 2026 7:00 AM - StreetInsider
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
May 27, 2026 7:00 AM - PR NewsWire
Form 4 Vanda Pharmaceuticals For: May 18 Filed by: Mitchell Stephen Ray
May 20, 2026 4:50 PM - SEC Filing
Form SCHEDULE 13G Vanda Pharmaceuticals Filed by: STATE STREET CORP
May 12, 2026 12:18 PM - SEC Filing
Vanda Pharmaceuticals (VNDA) PT Lowered to $21 at H.C. Wainwright
May 11, 2026 6:59 AM - StreetInsider
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
May 7, 2026 6:44 PM - PR NewsWire
Form 10-Q Vanda Pharmaceuticals For: Mar 31
May 7, 2026 7:02 AM - SEC Filing
Form 8-K Vanda Pharmaceuticals For: May 06
May 6, 2026 4:07 PM - SEC Filing
Vanda Pharmaceuticals (VNDA) Misses Q1 EPS by 13c, provides guidance
May 6, 2026 4:03 PM - StreetInsider
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
May 6, 2026 4:01 PM - PR NewsWire
Form EFFECT Vanda Pharmaceuticals
May 6, 2026 6:08 AM - SEC Filing
Vanda launches NEREUS motion sickness drug after 40-year gap
May 4, 2026 8:02 AM - StreetInsider
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
May 4, 2026 8:00 AM - PR NewsWire
Vanda launches motion sickness drug NEREUS after 40-year gap
May 1, 2026 4:36 PM - StreetInsider
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
May 1, 2026 4:36 PM - PR NewsWire
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
April 29, 2026 4:30 PM - PR NewsWire
Form SCHEDULE 13G/A Vanda Pharmaceuticals Filed by: BlackRock Portfolio Management LLC
April 29, 2026 4:11 PM - SEC Filing
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
April 28, 2026 7:13 PM - PR NewsWire
Form 4 Vanda Pharmaceuticals For: Apr 22 Filed by: Duncan Charles Cliff
April 24, 2026 4:37 PM - SEC Filing
Form 3 Vanda Pharmaceuticals For: Apr 22 Filed by: Duncan Charles Cliff
April 24, 2026 4:35 PM - SEC Filing
Form ARS Vanda Pharmaceuticals For: Dec 31
April 23, 2026 7:20 PM - SEC Filing
Form DEFA14A Vanda Pharmaceuticals
April 23, 2026 7:20 PM - SEC Filing
Form DEF 14A Vanda Pharmaceuticals For: Jun 04
April 23, 2026 7:19 PM - SEC Filing
Form 8-K Vanda Pharmaceuticals For: Apr 22
April 22, 2026 5:23 PM - SEC Filing
Vanda Pharmaceuticals adds Dr. Charles Duncan to board of directors
April 22, 2026 5:14 PM - StreetInsider
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
April 22, 2026 5:14 PM - PR NewsWire
Form 3 Vanda Pharmaceuticals For: Apr 01 Filed by: Polymeropoulos Christos Vasilios Mihael
April 13, 2026 5:39 PM - SEC Filing
Form 3 Vanda Pharmaceuticals For: Apr 01 Filed by: Howell Scott Laverne
April 13, 2026 5:37 PM - SEC Filing
Vanda Pharmaceuticals opposes FDA proposal to extend drug review timelines
April 9, 2026 11:03 AM - StreetInsider
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
April 9, 2026 11:03 AM - PR NewsWire
H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)
April 9, 2026 6:42 AM - StreetInsider
Vanda starts trial of NEREUS drug for GLP-1 side effects
April 8, 2026 4:45 PM - StreetInsider
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
April 8, 2026 4:45 PM - PR NewsWire
Form 8-K Vanda Pharmaceuticals For: Mar 29
April 2, 2026 4:31 PM - SEC Filing
Form SCHEDULE 13G/A Vanda Pharmaceuticals Filed by: VANGUARD GROUP INC
March 27, 2026 1:56 PM - SEC Filing
Truist Securities on Vanda Pharmaceuticals (VNDA): EMA news is just 'noise'
March 27, 2026 11:24 AM - StreetInsider
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods
March 19, 2026 4:35 PM - PR NewsWire
Full Article List
